Edition:
India

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

14.04USD
1:30am IST
Change (% chg)

$-0.31 (-2.16%)
Prev Close
$14.35
Open
$14.57
Day's High
$14.57
Day's Low
$13.73
Volume
141,195
Avg. Vol
207,977
52-wk High
$16.28
52-wk Low
$4.04

Latest Key Developments (Source: Significant Developments)

Marinus Provides Corporate Update On Phase 3 Raise Trial In Status Epilepticus
Friday, 25 Sep 2020 

Sept 24 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PROVIDES CORPORATE UPDATE ON PHASE 3 RAISE TRIAL IN STATUS EPILEPTICUS (SE).MARINUS PHARMACEUTICALS INC - SATISFIED FDA'S PROTOCOL-SPECIFIC QUESTIONS FOR PHASE 3 TRIAL IN REFRACTORY STATUS EPILEPTICUS.MARINUS PHARMACEUTICALS INC - INTENDS TO BEGIN ENROLLMENT FOR REGISTRATIONAL PHASE 3 CLINICAL TRIAL IN RSE.MARINUS PHARMACEUTICALS INC - OVER 55 OUT OF PROJECTED 80 SITES HAVE BEEN SELECTED FOR TRIAL PARTICIPATION.MARINUS PHARMACEUTICALS INC - CONTINUES TO ANTICIPATE TOP-LINE DATA FROM PHASE 3 RAISE TRIAL IN 1H 2022.  Full Article

Marinus Appoints Scott Braunstein As Chairman Of Board
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS ANNOUNCES LEADERSHIP TRANSITION.SAYS SCOTT BRAUNSTEIN APPOINTED CHAIRMAN OF THE BOARD.MARINUS HAS RETAINED AN EXECUTIVE SEARCH FIRM TO IDENTIFY CASHMAN'S SUCCESSOR AS CEO..MARINUS PHARMACEUTICALS - CHIEF EXECUTIVE OFFICER, CHRISTOPHER M. CASHMAN, WILL LEAVE COMPANY EFFECTIVE MARCH 18.SCOTT BRAUNSTEIN HAS BEEN APPOINTED EXECUTIVE CHAIRMAN.  Full Article

Marinus Pharmaceuticals Says Entered Into Underwriting Agreement To Offer 12 Mln Shares
Saturday, 15 Dec 2018 

Dec 14 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS INC - ENTERED INTO AN UNDERWRITING AGREEMENT TO OFFER 12 MILLION SHARES AT $3.75PER SHARE - SEC FILING.MARINUS PHARMACEUTICALS INC - OFFERING SIZE IS EXPECTED TO BE $45.0 MILLION.  Full Article

Marinus Pharmaceuticals Prices Public Offering Of 12 Mln Shares At $3.75/Shr
Thursday, 13 Dec 2018 

Dec 12 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.0 MILLION COMMON SHARES PRICED AT $3.75PER SHARE.  Full Article

Marinus Pharmaceuticals Announces Public Offering Of Common Stock
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 12.0 MILLION COMMON SHARES.MARINUS PHARMACEUTICALS - TO USE PROCEEDS TO ADVANCE PRECLINICAL AND CLINICAL DEVELOPMENT OF GANAXOLONE, INCLUDING CLINICAL TRIAL EXPENSES.  Full Article

Marinus Pharmaceuticals phase 2 clinical trial data show long-term effectiveness of Ganaxolone in reducing seizure frequency in CDKl5 deficiency disorder patients
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS PHASE 2 CLINICAL TRIAL DATA SHOW LONG-TERM EFFECTIVENESS OF GANAXOLONE IN REDUCING SEIZURE FREQUENCY IN CDKL5 DEFICIENCY DISORDER PATIENTS.MARINUS PHARMACEUTICALS INC - PREDICTIVE BIOMARKER ALSO IDENTIFIED IN PCDH19-RELATED PEDIATRIC EPILEPSY.MARINUS PHARMACEUTICALS INC - AVERAGE SEIZURE FREQUENCY FOR PATIENTS HAS CONTINUED TO IMPROVE, NOW TO A 66 PERCENT REDUCTION..MARINUS PHARMACEUTICALS INC - TWO PATIENTS NOTED MILD INCREASES IN SEIZURE FREQUENCY AT 12 OR 18-MONTH MARKS RELATIVE TO SIX MONTHS.  Full Article

Marinus genetic epilepsy drug meets main goal of late-stage study

Marinus Pharmaceuticals Inc said on Monday its experimental treatment for a rare type of genetic epilepsy called CDKL5 deficiency disorder (CDD) met the main goal of reducing seizure frequency in patients in a late-stage trial.